Eli Lilly's Chief Financial Officer said during the performance conference call that injectable GLP-1 drugs are still the core growth driver, and 3 out of every 4 patients newly using this type of drug choose the injectable dosage form.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.